ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Pregnancy exacerbates PNH-related manifestations. Complement inhibition has improved both maternal and fetal outcomes. Most hematologists agree that the benefits of complement inhibition during ...

Clone size and symptom burden dictate how often patients with PNH require follow-up. Hematology assessments during routine visits should include flow cytometry, CBC, D-dimer levels, and serum ferritin ...

Basel, June 12, 2025 – Novartis announced positive results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta ® (iptacopan) in adult ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disease in which the immune system breaks apart the red blood cells (RBCs) in the body. The medical term for this premature rupture of RBCs is ...

AJMC ®: Paroxysmal nocturnal hemoglobinuria (PNH) is 1 of several complement-driven diseases. Can you describe its clinical presentation? DE CASTRO: PNH presents heterogeneously. One of the 3 ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disease that can cause fatigue due to anemia. PNH is closely associated with fatigue due to a loss of red blood cells, leading to anemia. This ...

Ilene Weitz, MD, details a few abstracts on paroxysmal nocturnal hemoglobinuria (PNH) treatments that will be presented at ASH 2024, particularly data on danicopan as an add-on to ravulizumab or ...

For patients with paroxysmal nocturnal hemoglobinuria (PNH), crovalimab has emerged as an additional treatment option with a similar safety and efficacy profile to eculizumab, Crovalimab is a novel ...

The US Food and Drug Administration (FDA) recently approved two biosimilars to Soliris for the treatment of two rare diseases — paroxysmal nocturnal hemoglobinuria (PNH), a debilitating and ...

Healio spoke with Marcel P. Devetten, MD, associate professor of oncology and hematology at University of Nebraska Medical Center, about multidisciplinary care in paroxysmal nocturnal hemoglobinuria ...

Apellis Pharmaceuticals is taking a victory lap. Less than two weeks after the FDA approved Apellis’ C3 inhibitor pegcetacoplan, marketed as Empaveli, for patients with a rare blood disorder known as ...